Clinical trials: Drug-drug Interaction
Human Volunteers
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
The purpose of this study is to estimate the effect of multiple oral doses of PF-03882845 on the pharmacokinetics of simvastatin and simvastatin acid in healthy, adult subjects.
- Trial name
- NCT01445860
- Testing
- Simvastatin/PF-03882845
- Where
- Singapore
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Bacterial
Relative Bioavailability Study in Healthy Subjects
Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation.
- Trial name
- PDF112034 (NCT00924911)
- Testing
- GSK1322322
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or…
- Trial name
- NCT06783192
- Testing
- MK-8527, LNG/EE
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
The purpose of this study is to determine the effects of tivantinib on the pharmacokinetics of omeprazole, s-warfarin, caffein, midazolam, or digoxin in patients with cancer.
- Trial name
- NCT01517399
- Testing
- tivantinib, omeprazole, s-warfarin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Daiichi Sankyo
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
- Trial name
- NCT00990821
- Testing
- 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate
This is an open-label, randomized, 2-period crossover, inpatient study to be performed in healthy subjects. The study will consist of 2 treatment periods: There will be 2 parallel cohorts of 12 subjects each who will be enrolled…
- Trial name
- NCT00369304
- Testing
- pharmacokinetic (how the body absorbs and eliminates) interaction
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive [Ethinyl estradiol/Norethisterone (EE/NET)] in healthy female participants.
- Trial name
- NCT07215806
- Testing
- Evobruitnib, Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy
Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)
The purpose of the study is to to assess the effect of multiple oral doses of ZD4054 (Zibotentan) on the pharmacokinetics of a CYP450 3A Probe (midazolam) in healthy male subjects.
- Trial name
- NCT00709553
- Testing
- midazolam, ZD4054
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Pharmacokinetics of ASP1941
A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol
This study is to assess the pharmacokinetic interaction between ASP1941 and Miglitol in healthy volunteers.
- Trial name
- NCT01099839
- Testing
- ASP1941, Miglitol
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Multiple Sclerosis
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
This is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy…
- Trial name
- NCT06064539
- Testing
- Tolebrutinib, gemfibrozil, rifampicin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it.
- Trial name
- NCT04586920
- Testing
- LY3509754, Itraconazole, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients.
- Trial name
- NCT05208047
- Testing
- CGT9486, Sunitinib, Midazolam
- Where
- 126 sites in United States, Argentina and 20 more
- Volunteers
- 482 people
- Sponsor
- Cogent Biosciences, Inc.
Idiopathic Pulmonary Fibrosis
A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403 mg/day pirfenidone and to investigate…
- Trial name
- NCT02606877
- Testing
- nintedanib, pirfenidone
- Where
- 9 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Advanced and Metastatic Breast Cancer
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.
- Trial name
- NCT05052437
- Testing
- Utidelone Injection; capecitabine, Utidelone
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Solid Cancers
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with…
- Trial name
- NCT00927589
- Testing
- carboplatin, docetaxel, trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 59 people
- Sponsor
- Genentech, Inc.
Cancer
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
The purpose of this study is to assess the effect LY2603618 on a protein [enzyme cytochrome P (CYP) 2D6] which is involved in the metabolic pathway of Desipramine in participants with cancer.
- Trial name
- NCT01358968
- Testing
- LY2603618, Desipramine, Pemetrexed
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteer
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
A Phase I, open label, randomized, three period, one-way, two cohort, adaptive crossover study to evaluate the effect of darunavir/ritonavir plus etravirine and lopinavir/ritonavir plus etravirine on GSK1349572 pharmacokinetics…
- Trial name
- NCT00867152
- Testing
- Darunavir, Etravirine, Ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
The main purpose of this study is to evaluate the effects of multiple doses of LY3537982 on the pharmacokinetics (PK) of digoxin (a P-glycoprotein [P-gp] substrate), rosuvastatin (a breast cancer resistance protein [BCRP)]…
- Trial name
- NCT06111521
- Testing
- LY3537982, Digoxin, Rosuvastatin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Neoplasms
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
The primary objective of the present study is to investigate the influence of co-administration of itraconazole and volasertib on the pharmacokinetic profile of volasertib without co-administration of itraconazole.
- Trial name
- NCT01772563
- Testing
- volasertib, itraconazole
- Where
- 2 sites in Hungary
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Digoxin
Drug Interaction Study of Isavuconazole and Digoxin
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of digoxin in healthy adult subjects.
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Digoxin, Healthy Volunteers
- Trial name
- NCT01582412
- Testing
- Isavuconazole, digoxin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.